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MicroRNAs (miRNA) are one class of the small regulatory RNAs that can impact the expression 
of numerous genes including incretin hormones and their G protein-coupled receptors. Incretin 
peptides, including GLP-1, GLP-2, and GIP, are released from the gastrointestinal tract and have 
an crucial role in the glucose hemostasis and pancreatic beta-cell function. These hormones and 
their analogs with a longer half-life, glucagon like peptide-1 receptor agonists (GLP1RA), modify 
the expression of miRNAs. Dipeptidyl peptidase IV (DPP-4) is an enzyme that degrades the 
incretin hormones and is inactivated by DPP-4 inhibitors, which are a class of compounds used in 
the management of type 2 diabetes. DPP-4 inhibitors may also increase or reduce the expression 
of miRNAs. In this review, we describe the possible interactions between miRNAs and incretin 
hormones and the relevance of such interactions to physiological processes and diseases. 











Gene expression can be modulated in different levels of the protein production process from the 
initiation (transcription) to the end (post-translational modification), particularly in the eukaryotic 
cells by several regulatory factors [1]. MicroRNAs (miRNA) are short noncoding RNAs that 
contain 18-22 nucleic acids that are encoded by their genes within the genome. These regulators 
bind to 3`UTR of mature messenger RNA (mRNA) and have an essential role in RNA silencing 
through the RNA-induced silencing complex (RISC) (Fig.1) [2]. In this review, we describe the 
effects of miRNAs on the expression of incretin hormones and their effect on various metabolic 
processes. Certain miRNAs reduce the expression of gut-derived peptide hormones, especially 
glucagon-like peptide-1 (GLP-1), and may impair glucose homeostasis along with beta-cell 
dysfunction associated with diabetes. In addition, miRNAs affect the incretin receptors as well. 
Glucagon-like peptide-1 receptor (GLP-1R) is a receptor belonging to the G-protein family and is 
involved not only with glucose homeostasis but also with neuroprotection and memory [3]. 
Incretins are peptides derived from the gastrointestinal family of hormones that have a crucial role 
in various metabolic functions, including lipoprotein metabolism and lipid accumulation, anti-
inflammatory effect on the immune system and glucose homeostasis [4-7]. Due to the different 
mechanisms by which these molecules induce insulin sensitivity and secretion besides reducing 
the glucagon secretion, they are considered as one of the important therapeutic agents in the 
management of diabetes [8]. The incretin peptides are influenced by the miRNAs, however, 
incretin hormones may regulate miRNAs expression as well. Studies have shown that most of 
these up- and down-regulation effects of incretins are related to the lipid and glucose metabolism. 
The GLP1R agonists or incretins are now considered as mainline therapy for the management of 
type 2 diabetes (T2D) [9]. It has been shown that GLP1R agonists have an effect on the expression 
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of miRNAs and are considered as a regulator for both increasing and decreasing the level of 
miRNA expression. 
Dipeptidyl peptidase 4 (DPP-4) is an enzyme that degrades the incretin hormones. The DPP-4 
inhibitors block the action of DPP-4 and reduce the blood glucose by increasing half-life of gut-
derived peptides [8]. The last section of this review describes the relationship between DPP-4 
inhibitors and expression of various miRNAs.  
 
1. Effects of miRNAs in regulating incretin hormones 
The miRNA molecules are small, non-coding RNAs containing about 22 nucleic acids that have 
emerged as a gene expression regulator in the past decade [10]. Several studies indicate that along 
with their regulatory roles, miRNAs also can be used both as biomarkers and therapeutic targets 
for various diseases [11, 12]. Like many proteins and peptides, the expression of incretins may be 
influenced by RNA interference, particularly miRNAs that can alter biological processes (Table 
1). Some miRNAs have a stimulatory role in the expression of incretin hormones and increase the 
secretion of GLP-1 [13, 14]. One study suggested that lipid A (or endotoxin) can reduce the risk 
of T2D by improving the pancreatic β-cell function. Lipopolysaccharide (LPS) upregulates both 
interleukin (IL)-6 expression and miR-155 that promote insulin secretion, increase GLP-1 
production and suppress v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B 
(Mafb). The miR-155 increases IL-6 secreted from the β-cell by which pancreatic cells have more 
tendencies to produce GLP1 towards glucagon hormones [13]. Another study showed that 
alterations in the composition of gut microbiota by fructooligosaccharides (FOS) changed the host 
gene expression. FOS is a non-digestible oligosaccharide composed of fructose units and has 
beneficial physiological effects, such as decreasing the levels of serum cholesterol and 
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triacylglycerols, low sweetness intensity, and is used as a prebiotic agent. Fermentable dietary FOS 
decreased miR-33 expression in the liver, thereby increasing the production of GLP-1 hormone 
and improving insulin sensitivity [14].  
In contrast, several miRNAs reduce the incretin levels and can play a role in the development of 
diabetes. Pan and colleagues in 2017, demonstrated that miR-192 promoted type 1 diabetes (T1D) 
in the patients by suppressing the expression of GLP-1 and reducing the secretion of insulin. 
Moreover, overexpression of miR-192 not only inhibited cell proliferation but also facilitated 
apoptosis in the pancreatic β cell, although the exact mechanism of action is unclear [15]. The 
reduction of incretin hormones mediated by miRNAs may also occur following a disease. For 
instance, pancreatic cancer (PC) is associated with diabetes mellitus, although the exact 
mechanism is not yet been fully elucidated. PC-derived exosomes upregulated miRNAs (miR-
6796-3p, miR-6763-5p, miR-4750-3p and miR-197-3p) by which the expression of incretin 
hormones was remarkably reduced. Downregulation of GLP-1 and glucose-dependent 
insulinotropic polypeptide (GIP)  resulted in the suppression of proprotein convertase 
subtilisin/kexin (PCSK)1/3 and PCSK2, which are essential enzymes that are required for the post-
translational processing [16].  
The gut microbiota (GM) dysbiosis involves different miRNA target genes related to the 
cholesterol and glucose metabolism. Considering these changes were tissue-specific, in colon-2W, 
downregulation of miR-1955-5p and upregulation of miR-466n-3p, miR-1197-3p, miR-6356, 
miR-875-5p, miR-7679-5p, and miR-542-3p enhanced the expression of ADCY6 and KCNN1 
genes, which are related to the GLP1 secretion. Therefore, dysbiotic GM disturbs the glucose 
hemostasis by reducing the GLP1 mediated insulin signaling pathways and insulin sensitivity in 
the colon and liver [17].  
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miRNAs also can have a dual role as a regulator and suppressor in the incretin expression. Knudsen 
and coworkers in 2015 explained the crucial role of miRNAs in the enteroendocrine differentiation 
and development; moreover, they described several miRNAs expressed when the cells commit to 
a particular epithelial cell lineage. They found that miR-7b-5p, let-7g-3p, miR-582-3p, and miR-
375 are upregulated in the mature enteroendocrine cells. Since miR-582 was detected in both CCK-
eGFP+ enteroendocrine and non-enteroendocrine cells, it may act as a suppressor for stem cells. 
Among these, miR-375 is highly expressed in all intestinal cells and has a dual role as an inhibitor 
in the intestinal stem cells of organoid cultures or as a regulator in the mature cells. Furthermore, 
miR-375 is also required for the glucose-regulated insulin secretion by maintaining the beta-cell 
mass and their function [18]. As described above, miRNAs may have regulatory effects (up- 
and down-regulation) on incretin hormone expression that have an essential role in developing 
metabolic diseases such as diabetes (Fig.2). 
 
2. miRNAs and expression of incretin receptors  
Incretins are released after meals and affect the pancreatic cells when they bind to their receptors. 
Both GLP and GIP receptors are members of the G protein family that initiate a signaling cascade, 
thereby increase adenylate cyclase enzyme to produce further cAMP in the pancreatic β-cells and 
ultimately stimulate insulin secretion [19]. The miRNAs can modulate the expression of incretin 
receptors (Table 2), some of which decrease the expression of the GLP-1 receptor. For the first 
time, an animal study showed that incretin receptors are under the control of miRNAs, and miR-
204 is capable of binding to 3UTR of GLP1R, thereby inhibited the expression of this receptor 
significantly. Hence, by blocking the miR-204, the level of GLP1R increased and improved 
glucose tolerance and insulin secretion [20]. miR-665 reduces the GLP1 receptor expression as 
well and elevates cell apoptosis via inhibiting GLP1 and cAMP function in heart failure (HF) rats. 
7 
 
Hence, the downregulation of miR-665 activates the cAMP signaling pathway via binding to 
GLP1R which represses apoptosis of cardiac cells and consequently improves the cardiac function 
[21]. Another animal study on miR-338 demonstrated that bisphenol A (BPA) exposure time-
dependently changed the level of miR-338. Bisphenol A (BPA) is a type of endocrine-disrupting 
chemical that is used to make plastics products and a variety of common consumer goods. BPA 
interacts with nuclear receptors; for instance, it can bind to the nuclear estrogen receptors (ERs) 
like the effects of natural hormones and keep these receptors in the active conformation {Wei, 
2017 #164}, besides has been shown that BPA can disorder glucose homeostasis and impair 
pancreatic islet function. Long-term BPA exposure upregulated the miR-338 thereby suppressing 
the GLP1.  miR-338 has been associated with GLP1R as well as Pdx1 expression that is involved 
in islet β cell function and survival, respectively [22]. The expression of miR-338 also decreased 
during obesity and pregnancy by stimulating the G protein-coupled estrogen receptor (GPR30) 
and the glucagon-like peptide1 receptor (GLP1R) [23]. In a study on two groups of laboratory 
animals (old and young) showed that miRNA might increase GLP1R by olive oil consumption. 
They showed that phenolic compounds in olive oil such as oleuropein, oleocanthal, hydroxy-
tyrosol, and tyrosol downregulated miR-27 involved in the control of GLP1R gene expression, 
thereby reduced anxiety in the old animals. It is noteworthy to mention that GLP1R has a 
significant role in neuroprotection besides glucose metabolism and insulin secretion [3]. 
 
3. Regulation of miRNA expression by incretins 
Incretin hormones are gut-derived peptides, which stimulate insulin secretion pathway by binding 
to G-protein coupled receptors present on the surface of pancreatic beta cells and other tissues [9]. 
GLP-1 and GIP are the most prominent members in this family of hormones that are secreted by 
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the gastrointestinal tract. Intestinal enteroendocrine L-cells located in the ileum and colon produce 
glucagon-like peptide-1(GLP-1) and glucagon-like peptide-2(GLP-2), whereas glucose-dependent 
insulinotropic polypeptide (GIP) are released from the K-cells in the duodenum (Fig.3) [24]. These 
hormones both down- and up-regulate miRNAs that might affect gene expression (Table 3) [25]. 
GLP-1 is a peptide with a very short half-life composed of 31 amino acids. This hormone has 
several pharmacological effects that ameliorate hyperglycemia by increasing insulin secretion and 
insulin sensitivity as well (Fig.4), reducing oxidative stress [8]. Studies have shown that alteration 
of GLP-1 can affect the expression of some miRNAs. Therefore, any natural, semi-synthetic, and 
synthetic compounds that will increase the amount of GLP1 may lead to the modification of 
expression of miRNAs. GLP-1 peptides have an inhibitory effect on the expression of certain 
miRNAs. Four of such miRNAs are miR-758, miR-27a, miR-192, and miR-23a have been shown 
to induce ATP-binding cassette transporter (ABCA1) protein and thereby regulate lipid 
homeostasis and inhibit the hepatocyte apoptosis [26-29]. Yao et al. in 2018 reported the 
correlation between GLP1 and cholesterol-induced apoptosis. They found that GLP1 can 
ameliorate the lipid abnormalities associated with T2D by downregulating miR-758 and 
enhancement of ABCA1. This protein is necessary for the control of cholesterol homeostasis; 
however, the exact mechanism is still not clear [26]. They have also showed in another study that 
the positive effect of GLP1 on cholesterol accumulation and improved β-cells dysfunction through 
the reduction of miR-27a, which results in increased expression of ABCA1 protein and modulation 
of intracellular cholesterol hemostasis [27]. Downregulation of miR-192 improved lipid 
metabolism and attenuated total cholesterol through a similar mechanism [28].  The 
downregulation of miR-23 by GLP1 leads to a reduction of apoptosis of hepatocyte G2 cells by 
inducing mitochondrial protective gene PGC-1a. The expression of uncoupling protein 2 (UCP2) 
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was increased, thereby reducing apoptotic death and increased cell survival in response to GLP1 
[29]. 
The cAMP is a second messenger responsible for multiple physiological functions in living cells. 
Some natural or synthetic compounds can increase the synthesis of cAMP from ATP. Forskolin is 
a plant derived compound with diverse pharmacological effects that increases the cellular cAMP 
concentration by stimulating adenylyl cyclase enzyme which is involved in the glucose and lipid 
mechanism. cAMP is regulated by the transcription factor cAMP-responsive element-binding 
protein (CREB), which binds to diverse miRNAs such as miR-212 and miR-132. Malm, H.A. and 
coworkers in 2015 demonstrated that the overexpression of miR-212 and miR-132 by 
enhancement of cAMP in response to GLP1 and forskolin could augment the insulin secretion and 
improve the βcells function. [30, 31]. GLP2 is another incretin hormone made up of 33 amino 
acids that are released from the L cells and can improve the function of hepatocytes by regulating 
glucose and lipid metabolism [32]. GIP, a 42‐amino‐acid peptide, has a significant role in various 
physiological processes as well [19]. Yan et al. in 2017 demonstrated that an oral glucose tolerance 
test (OGTT) increased the glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) and 
glucose-dependent insulinotropic polypeptide (GIP) that lead to overexpression of miR-375. This 
circulating miR is not released in the serum and liver abundantly, but a moderate expression was 
detected in the brain and CSF. Therefore, in response to incretin peptides secretion, several 
endocrine cell types express miR-375 with a diverse effect on lipid and glucose metabolism in the 
liver. In this study, the level of miR-375 increased after the administration of oral glucose and 
enhanced the incretin level. The GLP2 following nutrient uptake increases the level of miR-375 
and improves lipid and glucose metabolism. In contrast, knock out mir-375 results in reduced β-




4. Modification of miRNAs by incretin receptor agonists  
GLP-1R agonists (e.g., liraglutide & exendin-4) are incretin mimetics, which are used in the 
management of type 2 diabetes. There is growing evidence that GLP-R agonists can regulate the 
expression of various miRNAs (Tables 4 and 5). 
  
4.1. Liraglutide is an acylated human GLP-1 analogue, which has a protective effect on various 
tissues. Li et al. in 2016 investigated whether the antiapoptotic effect of liraglutide is due to the 
downregulation of miR-139-5p. Real-time quantitative RT-PCR results showed that treatment 
with liraglutide on cells resulted in the enhancement of mRNA and insulin receptor substrate-1 
(IRS1) protein by attenuating miR-139. The TUNEL and annexin V/propidium iodide staining 
demonstrated a reduction of apoptosis in the pancreatic tissue from diabetic rats [34]. The 
beneficial effect of liraglutide on pancreatic islet can enhance apoptosis in pancreatic α-cells by 
inhibiting the cAMP-PKA signal pathway and had an opposite effect in pancreatic β-cells as 
previously mentioned for GLP1, GLP2, and GIP, thereby increasing the cell viability [35].  
The protective effect of liraglutide on bones was studied in patients with diabetes. The expression 
of let-7c-2-3p, let-7a-1-3p, and miR-322-3p was more in patients with diabetes that was reduced 
by liraglutide treatment. The above-mentioned miRNAs blocked the expression of Wnt/β-catenin 
pathway genes, suggesting that liraglutide has a potential beneficial effect on metabolic bone 
disorders [36]. Liraglutide has vasoprotective effects by improving endothelial function by 
inhibiting miR-181a-5p, miR-93-5p, and miR-34a 5p expression as well as increasing the miR-
26a-5p expression. PTEN is a miR-26a-5p target gene, whereas Creb is a miR-181a-5p target, both 
of which control the balance between survival and death in various cell lines such as vascular 
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endothelial cells. Indeed, miRNA alteration by liraglutide could inhibit endothelial cell apoptosis 
via activating the PI3K-AKT-Bcl-2 pathway [37].  
Studies show that in addition to beneficial effects on glucose homeostasis, lipid metabolism is also 
influenced by liraglutide.  When the effects of liraglutide to prevent the development of 
nonalcoholic fatty liver disease (NAFLD) was investigated, it was shown that miR-124 could 
degrade adipose triglyceride lipase (ATGL) mRNA by binding to the 3UTR region. Liraglutide 
enhanced the ATGL and Sirtuin1 expression resulting in reduced lipid accumulation and 
inflammation in cells [38]. In another study, liraglutide through miR 192-5p attenuated lipid 
accumulation by reducing stearoyl-CoA desaturase 1 (SCD-1) [39]. Shen et al. investigated the 
alteration of miRNA expression in nonalcoholic fatty liver disease (NAFLD) (36). They showed 
that the expression of miR-34a, miR-21, miR-451 increased, whereas the expression of miR-183 
was decreased in an animal model with hepatic steatosis. miRNA next-generation sequencing 
results revealed that liraglutide decreased these miRNAs levels that are related to lipid metabolism, 
regulation of cell apoptosis, and oxidative stress response [40]. Eventually, the anti-breast cancer 
potential of liraglutide was reported by Zhao and colleagues in 2017, where they showed a dose-
dependent effect of liraglutide in patients with TD2 and breast cancer. miR-27 is highly expressed 
in many cancers, including breast cancer, and thereby the expression of AMP‐activated protein 
kinase catalytic subunit α2 (AMPKα2) was reduced. Treatment with liraglutide had a reverse effect 
on the miR-27 expression, increased AMPKα2 protein, and consequently suppressed cell 
proliferation in breast cancer [41]. 
 
4.2- Exenatide is another GLP1-R agonist and is used as an anti-diabetic medication for the 
management of T2D that can modulate the expression of miRNAs [Table 5]. The pharmacological 
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effects of exenatide influence multiple organs and tissues, including the pancreas, heart and 
kidneys by modulating different metabolic pathways. With regards to pancreatic β-cells, Exendin-
4 downregulates miR-375 through blocking its promotor mediated cAMP-protein kinase A (PKA) 
pathway. Since miR-375 has a negative effect on insulin secretion, treatment with Exendin-4 
increases the insulin response in pancreatic β-cells [42]. In high‐fat diet )HFD( mice, Exendin-4 
modulated miR-7, miR-9 and miR-375. The expression of miR-7 decreased significantly, the 
expression of mTOR increased and improved beta cells proliferation after treatment with a high 
dose of Exendin-4, but no differences were seen in a low dose of Exendin-4 treatment. miR-375 
also reduced with both high or low doses of Exendin-4 and its expression associated with 
stimulation of PDK-1, thereby beta cells function and insulin secretion increased. The miR-9 
showed similar results to miR-375 with a reduction of miR-9 at both high and low doses of 
Exendin-4 with improvement in GSIS and β-cell function [43]. A similar study compared the 
expression pattern of miRNAs in exendin4 treatment mice at three (high, middle and low) doses 
with a control group. Real-time fluorescent quantitative PCR demonstrated a reduction of miR-
19a, miR-19b, and miR-22 and an increase of miR-1 expression. These four distinct miRNA-target 
genes are related to glucose metabolism, cell proliferation and apoptosis; hence significant 
alterations were observed on blood glucose and pancreatic tissue.  No atrophy or hypertrophy 
besides reducing the degree of fibrosis in pancreatic tissue was observed during histopathological 
analysis, thereby confirming the effective role of exendin-4 in promoting insulin secretion and 
protecting against pancreatic injury in diabetes [44].  
It has been shown that time-dependent bisphenol A (BPA) exposure can alter the expression of 
miRNAs. Short term exposure of (BPA) reduced the level of mir-338 via stimulating G protein-
coupled estrogen receptor 1 (GPR30) and long-term exposure upregulate miR-338 by repressing 
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glucagon-like peptide1 receptor (GLP1R). Bisphenol A reduced miR-338-pdx1, decreased ATP 
synthesis and insulin secretion in islets. After this BPA exposed cells when treated with exendin-
4 compensated for the defect of miR-338 and BPA in islet cells [22].  
Lee and colleagues in 2015, assessed alteration of miRNAs level after exenatide treatment in an 
HFD-induced mouse model of obesity. Exenatide attenuated the expression of miRNA-15a, 
124a,29c, and 375 in the pancreas along with miRNA-29c, 124a, and 146a in the liver, and 
eventually increased 15a, 29c, 124a, and 375 levels in serum. They concluded that improvement 
of insulin sensitivity with exenatide was related to the expression of miRNA-15a, 29c, 124a, and 
375 [45]. Apart from the positive effect of Exendin-4, Sun et al. investigated its role in the 
development of pancreatitis. miR-181, miR-148, miR-210 and miR-216a are considered as 
potential biomarkers for pancreatitis and with Exenatide treatment, no differences were found in 
the expression of relevant miRNAs with pancreatitis [46]. Exendin-4 has a positive effect on 
diabetic kidney disease (DKD) through the miR-192-GLP1R pathway. Exendin-4 decreases the 
expression of miR-192 and enhances the GLP-1 receptor level, which can ameliorate renal fibrosis 
[35]. Niu and colleagues in an animal study showed that Exendin-4 had a beneficial effect on the 
redox homeostasis in HFD rats. They found that Exendin-4 treatment decreased miR-376c 
expression in the HFD liver and enhanced the hepatic cystathionine-β-synthase (CBS( protein and 
GSH levels, thereby reducing the malondialdehyde level in these hyperlipidemic rats. Exendin-4 
did not influence the expression level of miR-376c in HepG2 cells and was reported only in the 
livers of rats fed with HFD [47].  
Concerning the effect of exenatide on cardiac function, Sassoon and coworkers investigated the 
impact of Exendin-4 in cardiac response to ischemia and reperfusion in swine as a larger animal 
model. They found that Exendin-4 treatment prevented the downregulation of miRs 378, 423-3p, 
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133a-5p, 361-3p, and 423-5p in lean swine during ischemia whereas enhanced expression of miR-
491 and miR-146a in obese swine.  
The role of GLP1 and exendin-4 in maintaining pluripotency in hematopoietic stem cells was 
investigated by Chayosumrit and coworkers in 2011. They found that the exendin-4 treatment 
effect during human embryonic stem cells (hESC) differentiation measured by quantitative real-
time PCR (qPCR) resulted in significant upregulation of miR-302a and miR-302c besides 
repression of SOX17 and FOXA2 expression. miR-302 families are crucial miRNAs to maintain 
self-renewal and hESC pluripotency [48]. 
 
5. DPP-4 inhibitors can modulate miRNAs expression 
 
Dipeptidyl peptidase IV (DPP-4), also known as CD26 is a surface antigen with enzymatic action 
that is encoded by the DPP4 gene and expressed on the diverse range of human cells particularly 
on the surface of epithelial cells and biological fluids. This protein degrades the incretin hormones 
and converts to their inactive natural form. Despite their short half-life and rapid cleavage, these 
gut hormones have a crucial role in regulating and controlling blood glucose. DPP-4 inhibitors are 
a class of anti-diabetic medications used to treat T2D via suppressing the DPP4 enzyme [49]. 
Besides these anti-diabetic effects, these therapeutic agents modify miRNAs expression resulting 
in various other metabolic effects [Table.6]. Birnbaum and coworkers compared linagliptin (a 
DPP-4i inhibitor) with exendin-4 (GLP1 receptor agonist) in cardiac dysfunction and 
inflammation. They found that both linagliptin and exendin-4 reduce the infarct size ischemia-
reperfusion animal models. Linagliptin also attenuated inflammation in patients with T2D through 
the suppression of the Nlrp3/ASC inflammasome and Toll-like receptor 4 (TLR4) expression 
mediated by various miRNAs. The upregulation of Let-7i and miR-146b by linagliptin treatment 
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activates p38, thereby reducing the inflammation and increasing the expression of collagen-1 and 
collagen-3 mainly via the action of miR-146 [50]. Renal fibrosis and resultant renal failure are 
some of the most typical complications in patients with diabetes. Kanasaki and colleagues 
demonstrated that linagliptin, a DD4- inhibitor, improved renal fibrosis in diabetic mice mediated 
by miR-29. miRNA array analysis showed that linagliptin induced the expression of miRNA 29 
by which TGF-b2–induced endothelial-to mesenchymal transition (EndMT) was suppressed. The 
antifibrotic effects of linagliptin are correlated with TGF-b1 and suppression of DPP-4 [51]. 
Overexpression of miR-200b results in 200-c modified lipid accumulation and fatty acid synthase 
(FAS) by inducing the expression of JUN gene and sterol regulatory element-binding protein 1 
(SREBP1) activation. In contrast, suppression of miRNA 200 increased triglyceride levels. 
Sitagliptin (DPP-4 inhibitor) might have a positive effect in reducing hepatic lipid accumulation 
associated with enhancing expression of miR-200 [52]. 
 
Conclusion 
Incretins are peptides released from the intestine, which have an effect on the pancreatic cells. 
miRNAs are small noncoding RNAs that bind to the 3’UTR region of mature mRNA and modify 
the gene expression mediated by the RISC complex, some of which can regulate the action of 
incretin hormones. Some miRNAs, including miR-155-5p and miR-33, increase the expression of 
incretin hormones, particularly GLP-1, thereby stimulating insulin secretion from pancreatic beta 
cells. On the contrary, miR-192, miR-6763, miR-197, miR-466n-3p, miR-1197-3p, miR-6356 and 
miR-875-5p downregulate the incretin expression and disturb the insulin secretion pathway. These 
miRNAs may have a dual role in controlling gene expression by both up or downregulation in 
different tissues like miR-375. miRNAs also modify incretin receptors. miR-204, miR-665 and 
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miR-338 suppress the GLP1-R expression, whereas miR-27a stimulates the GLP1-R in the 
cerebral cortex. The incretin hormones can also modulate the expression of miRNAs. GLP1 
upregulates miR-758, miR-27a, miR-192, miR-212 and miR-132 but downregulates miR-23 and 
miR-375. Both up and downregulation result in a reduction of blood glucose by improving beta-
cell function and increasing insulin secretion. There is growing evidence on the effect of medications 
for the treatment of diabetes linked with these peptide hormones such as GLP1R agonists and 
DPP-4 inhibitors that affect the expression of various miRNAs. Further experimental researches 
are warranted to fully elucidate these pathways, which are potential biomarkers and therapeutic 
targets. 
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Fig.1. MicroRNAs bind to 3UTR of mature mRNA and modulate gene expression through RISC complex (mRNA silencing) 
during the processes named post-translational modification. 
 
Fig.2. MicroRNAs regulate incretin expression by which may increase or decrease the probability of developing diabetes 
mellitus. 
 
Fig.3. The following nutrient uptake, incretin hormones GLP and GIP release from L-cells and K-cells respectively, and by 
binding to the receptors on the beta cells contribute to insulin secretion. Both of these have a short half-life and rapidly be 
deactivated by Dipeptidyl peptidase IV (DPP-4). 
 









Table.1. Effects of miRNAs in regulating incretin hormones and metabolic effects 
 






Promote insulin secretion by both 
increasing GLP-1 production and 
suppressing (Mafb) also induce 
defensive mechanism in islet 
stress  
Real-time PCR (qPCR) 
Animal (mice 
C57BL/6J) 





downregulated miR-33 by 
which enhanced the production 
of GLP-1 hormone and 









Induce T1DM by suppressing 
the expression of (GLP-1) and 
cell proliferation, moreover 
facilitate apoptosis in pancreatic 
β cell 
 
qRT-PCR and Western blot 
Animal (SD rat) 
Human cell line 
(NCI-H716) 
Mouse cell line 







Downregulation of GIP and 
GLP-1 by suppressing 
essential enzymes (PCSK1/3 
and PCSK2) 
Microarray and ELISA 













GM (gut microbiota) dysbiosis 
disturbed GLP1 mediated 
insulin signaling pathways by 
regulating these microRNAs 
that can alter the gene 









were up-regulated in the 
enteroendocrine cells 
dual role as a regulator and 
suppressor also associated 





















Decreased GLP1R expression 
significantly, so by blocking miR-
204 improved glucose tolerance and 
insulin secretion 






Suppression of GLP1R expression 
and cAMP signaling pathway that 
caused cell apoptosis in heart failure 





Time dependently BPA exposure 
can decrease the expression of GLP-








Reduced anxiety in the cerebral 




































Increased ABCA1 expression by 
downregulating miR-758 to regulate 
cholesterol homeostasis resulting from 
GLP1 or cholesterol effect 
 











May affect cholesterol accumulation 
and β-cells dysfunction by regulating 
the expression ofmiR-27a and 
ABCA1resulting from GLP1 or 
cholesterol effect 
 















Animal (SD rat) 
 










Increased expression of gene PGC-1a 
by downregulating miR-23a to inhibit 
hepatocyte apoptosis and also enhanced 
UCP2 to reduce apoptosis 
 













Activation of PKA in βcells mediated 
by cAMP elevation can augment 
glucose and GLP-1 stimulated insulin 
secretion 
 
















miRNA-375 target genes in the liver 


















Protected pancreatic β-cells by 
inhibiting their apoptosis & increasing 
the mRNA and protein levels of IRS1 
 
Animal (SD rat) 
 





(in pancreatic α-cells) 
 
mi-375↓ 
(in pancreatic β-cells) 
Increased cell apoptosis by inhibiting 




Improved cell viability via Activating 
cAMP-PKA signal pathway  




let-7c-2-3p, let-7a-1-3p, and 
miR-322-3p (more expressed in 
diabetes and then↓) 
 
Protective effect in bone metabolic 
disorders through reducing 
microRNA by which blocked Wnt/ 
βcatenin 
 









Inhibited endothelial cell apoptosis 
via activating the PI3K-AKT-Bcl-2 
pathway 
Animal (rat) [37] 
Liraglutide miR-124a↓ 
 
Reduced lipid accumulation by 








Reduce lipid accumulation by 
reducing expression of SCD-1 
 
Animal (SD rat) 





Protection effect on hepatic steatosis 




Inhibited miR-27a and increased 
AMPKα2 protein consequently 
suppression cell proliferation in breast 
cancer 
 




Table.5. Effect of Exenatide on microRNAs expression  
Molecule 
(receptor agonist) 




Increased insulin secretion by 
cAMP pathway 
 












miR-7↓↓ (at high dose) 
 
no difference in the levels of 
miR-7 (in low dose) 
 
miR-375↓↓↓ (at both high 
and low dose) 
 
miR-9↓↓ (at both high and 
low dose) 
 
Increased expression of mTOR 







β-cell preservation and 
enhance insulin release by 
stimulating of PDK-1 
 
Regulated gene OC-2 and 








miR-19a, miR-19b, miR-22↓ 
miRNA-1↑ 
Reduced the degree of fibrosis 
in pancreatic tissue and 
confirmed protecting effects of 
















Through both mechanisms and 
mediated miR-338-pdx1 
decreased ATP synthesis and 
insulin secretion in islets 
 
 
Activated GLP-1r to offset 









miRNA-15a, 124a,29c, and 
375 in the pancreas ↓ 
miRNA-29c, 124a, and 146a 
in the liver 
miRNA-15a, 29c, 124a, & 
375 in the serum↑ 
Improved insulin sensitivity in 
a high-fat diet (HFD)-induced 







miR-181, miR-148, miR-210 
and miR-216a  
 
No differences were found in 
the expression of relevant 










Improved renal fibrosis by 
increasing GLP-1 receptor  
 








level and had a beneficial 









Prevent the downregulation 
of miRs 378,423-3p, 133a-
5p, 361-3p, and 423-5p in 
lean swine during ischemia 
miRs 491, and 146a↑ in 
obese swine 
 
Decreased myocardial infarct 








Exendin-4 miR-302a* and miR302c*↑ 
Maintained pluripotency and 
inhibited apoptosis in hESCs 
 





















Let-7i-3p, Let-7i-5p,  
miR-21, and miR-146b↑ 
 
Attenuated inflammation in 
T2D patient by reducing 
TLR4, increasing the 
expression of collagen-1 & 









Induced miR29 by which 
was repressed TGF-B and 
DPP-4 and ameliorated 
kidney fibrosis 
Animal (mice) 




miR200b and miR200c↑ 
in the liver 
Reduced hepatic 
triglyceride by inducing 
JUN gene and SREBP1 
activation 
Animal (mice 
C57BL/6J) 
Human (liver 
biopsy) 
Cell line 
(NCTC1469 and 
Hep1-6) 
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